Systemic Sclerosis (Scleroderma) - Pipeline Review - H1 2014





Summary

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2014’, provides an overview of the Systemic Sclerosis (Scleroderma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction 8
Global Markets Direct Report Coverage 8
Systemic Sclerosis (Scleroderma) Overview 9
Therapeutics Development 10
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview 10
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis 11
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies 12
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes 15
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Systemic Sclerosis (Scleroderma) - Products under Development by Companies 20
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes 22
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 23
Genzyme Corporation 23
F. Hoffmann-La Roche Ltd. 24
Sanofi 25
GlaxoSmithKline plc 26
MedImmune, LLC 27
BioLineRx, Ltd. 28
FibroGen, Inc. 29
arGentis Pharmaceuticals, LLC 30
Celgene Corporation 31
Bayer AG 32
Active Biotech AB 33
Accentia Biopharmaceuticals, Inc. 34
NeoStem, Inc. 35
Digna Biotech, S.L. 36
Therametrics holding AG 37
Angion Biomedica Corp. 38
iBio, Inc. 39
Daval International Ltd. 40
vida therapeutics inc. 41
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 46
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
Stem Cell Therapy for Crohns Disease and Systemic Sclerosis - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
tocilizumab - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
riociguat - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
belimumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
paquinimod - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
disitertide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ARG-201 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
pomalidomide - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Aimspro - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SAR-100842 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
JBT-101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MEDI-551 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CC-220 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
P-17 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
disitertide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ANG-3070 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Stem Cell Therapy For Chronic Wound Healing And Scleroderma - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
acALY18 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
1D-11 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
20(OH)D3 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
tropisetron - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Peptides for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Egr-1 for Scleroderma - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
FG-3019 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
DasKloster-050101 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
EDP-34 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Drug for Autoimmune Disorders - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Drug for Fibrotic Diseases - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
cyclophosphamide - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Systemic Sclerosis (Scleroderma) - Recent Pipeline Updates 101
Systemic Sclerosis (Scleroderma) - Dormant Projects 125
Systemic Sclerosis (Scleroderma) - Discontinued Products 126
Systemic Sclerosis (Scleroderma) - Product Development Milestones 127
Featured News & Press Releases 127
Feb 25, 2014: Daval International Announces the Granting of Orphan Drug Designation by the FDA for AIMSPRO 127
Oct 07, 2013: "Treatment of Diffuse Systemic Sclerosis with AIMSPRO" Publication Features in October Edition of Annals of the Rheumatic Diseases Journal 127
Jan 03, 2013: Celtaxsys Initiates Phase I Study Of CTX-4430 Oral Treatment For Pulmonary Inflammation 128
Nov 30, 2012: Daval Announces Presentation Of Poster & Abstract On Phase II Study Of Hyperimmune Caprine Serum At ACR/ARHP 2012 Annual Meeting 128
Jul 30, 2012: Daval Announces Presentation Of Abstract On Results Of Encouraging Clinical Trends In Phase II Study Of Aimspro In Systemic Sclerosis At EULAR 2012 129
Oct 10, 2011: Daval Announces Positive Phase II Results For AIMSPRO As Monotherapy In Diffuse Scleroderma 129
Jun 23, 2011: FDA Grants Orphan Drug Status For Accentia's Revimmune Therapy In Systemic Sclerosis And Hemolytic Anemia 130
Feb 20, 2011: Daval International Announces Completion Of Phase II Trial Evaluating Safety And Efficacy Of AIMSPRO 131
Nov 18, 2010: COMP Recommends Orphan Drug Status To Active Biotech's 57-57 Project 131
Apr 22, 2010: Actelion Pharmaceuticals Announces Commercial Availability of Epoprostenol for Injection for the Treatment of Pulmonary Arterial Hypertension 132
Appendix 133
Methodology 133
Coverage 133
Secondary Research 133
Primary Research 133
Expert Panel Validation 133
Contact Us 134
Disclaimer 134

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2014 10
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Comparative Analysis by Unknown Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Systemic Sclerosis (Scleroderma) - Pipeline by Genzyme Corporation, H1 2014 23
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 24
Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H1 2014 25
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline plc, H1 2014 26
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H1 2014 27
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H1 2014 28
Systemic Sclerosis (Scleroderma) - Pipeline by FibroGen, Inc., H1 2014 29
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals, LLC, H1 2014 30
Systemic Sclerosis (Scleroderma) - Pipeline by Celgene Corporation, H1 2014 31
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2014 32
Systemic Sclerosis (Scleroderma) - Pipeline by Active Biotech AB, H1 2014 33
Systemic Sclerosis (Scleroderma) - Pipeline by Accentia Biopharmaceuticals, Inc., H1 2014 34
Systemic Sclerosis (Scleroderma) - Pipeline by NeoStem, Inc., H1 2014 35
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H1 2014 36
Systemic Sclerosis (Scleroderma) - Pipeline by Therametrics holding AG, H1 2014 37
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H1 2014 38
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H1 2014 39
Systemic Sclerosis (Scleroderma) - Pipeline by Daval International Ltd., H1 2014 40
Systemic Sclerosis (Scleroderma) - Pipeline by vida therapeutics inc., H1 2014 41
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Stage and Target, H1 2014 45
Number of Products by Stage and Mechanism of Action, H1 2014 48
Number of Products by Stage and Route of Administration, H1 2014 50
Number of Products by Stage and Molecule Type, H1 2014 52
Systemic Sclerosis (Scleroderma) Therapeutics - Recent Pipeline Updates, H1 2014 101
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2014 125
Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2014 126

List of Figures
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2014 10
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 42
Number of Products by Top 10 Target, H1 2014 43
Number of Products by Stage and Top 10 Target, H1 2014 44
Number of Products by Top 10 Mechanism of Action, H1 2014 46
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 47
Number of Products by Top 10 Route of Administration, H1 2014 49
Number of Products by Stage and Top 10 Route of Administration, H1 2014 50
Number of Products by Top 10 Molecule Type, H1 2014 51
Number of Products by Stage and Top 10 Molecule Type, H1 2014 52